Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Premarketing observational studies of population pharmacokinetics of new drugs.

Literature DB >> 3931953

Premarketing observational studies of population pharmacokinetics of new drugs.

L B Sheiner, L Z Benet.

Abstract

Mesh：

Substances：

Year: 1985 PMID： 3931953 DOI： 10.1038/clpt.1985.212

Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875

Keyword Cloud
Cited

× No keyword cloud information.

26 in total

1. Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis.

Authors: S C Olson; H Bockbrader; R A Boyd; J Cook; J R Koup; R L Lalonde; P H Siedlik; J R Powell
Journal: Clin Pharmacokinet Date: 2000-05 Impact factor: 6.447

2. Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Authors: J H M Schellens; B Heinrich; M Lehnert; M E Gore; S B Kaye; P Dombernowsky; R Paridaens; A T van Oosterom; J Verweij; W J Loos; H Calvert; N Pavlidis; H Cortes-Funes; J Wanders; M Roelvink; C Sessa; K Selinger; P S Wissel; T Gamucci; A R Hanauske
Journal: Invest New Drugs Date: 2002-02 Impact factor: 3.850

Review 3. Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Authors: Goonaseelan Colin Pillai; France Mentré; Jean-Louis Steimer
Journal: J Pharmacokinet Pharmacodyn Date: 2005-11-07 Impact factor: 2.745

Premarketing observational studies of population pharmacokinetics of new drugs.

1. Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis.

2. Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Review 3. Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

4. Population pharmacokinetics: theory and practice.

Review 5. Population pharmacokinetics. A regulatory perspective.

6. A semiparametric method for describing noisy population pharmacokinetic data.

7. Multiple-dose pharmacokinetics of a long half-life drug: contributions of mathematical modeling.

8. Evaluation of population (NONMEM) pharmacokinetic parameter estimates.

9. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

Review 10. Identification of populations at risk in drug testing and therapy: application to elderly patients.